The tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) was heralded as a promising candidate for use clinically as a targeted therapeutic with research demonstrating that the agent had the ability to effectively inhibit different tumour types while displaying minimal toxicity on normal healthy cells. The gene discussed is TNFSF10; the disease is neoplasm.